Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920984 | 0.89 | MC4R (0.44) | KMT2APKMSIGMAR1KDM1ACARM1 | |
| SCHEMBL3462094 | 0.89 | ADRA1D (0.47) | SIGMAR1CARM1PRMT6L3MBTL1HTR4 | |
| SCHEMBL4437678 | 0.83 | SIGMAR1 (0.44) | KMT2APKMSIGMAR1CARM1PRMT6 | |
| SCHEMBL16446567 | 0.83 | SIGMAR1 (0.44) | SIGMAR1CARM1PRMT6L3MBTL1HTR4 | |
| SCHEMBL19924787 | 0.83 | SIGMAR1 (0.44) | SIGMAR1CARM1PRMT6L3MBTL1ADRA1D | |
| SCHEMBL27570291 | 0.83 | LTA4H (0.48) | KMT2APKMSIGMAR1KDM1ACARM1 | |
| SCHEMBL8144691 | 0.83 | LTA4H (0.48) | KMT2APKMSIGMAR1CARM1PRMT6 | |
| SCHEMBL23711916 | 0.80 | L3MBTL1 (0.50) | KMT2APKMSIGMAR1L3MBTL1HTR4 | |
| SCHEMBL27906246 | 0.80 | SIGMAR1 (0.42) | KMT2ASIGMAR1CARM1PRMT6L3MBTL1 | |
| SCHEMBL16795225 | 0.80 | MAPK1 (0.50) | SIGMAR1HTR4ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-18 | — | — | US | disclosed |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4259118-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | The Scripps Research Institute (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022125989-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-3298011-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11091509-B2 | HPPK inhibitors useful as antibacterial agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-08-17 | — | — | US | disclosed |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20190241605-A1 | HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2019-08-08 | — | — | US | disclosed |
| US-20190233418-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-08-01 | — | — | US | disclosed |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| CN-102391251-A | Chemokine receptor antagonists | NOVARTIS AG | 2012-03-28 | — | — | CN | disclosed |
| EP-2326327-A2 | ANALOGS OF INDOLE-3-CARBINOL AND THEIR USE AS AGENTS AGAINST INFECTION | SRI International (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| WO-2010033198-A2 | ANALOGS OF INDOLE-3-CARBINOL AND THEIR USE AS AGENTS AGAINST INFECTION | SRI INTERNATIONAL (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2008071981-A1 | PIPERIDINES FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071962-A1 | PTERIDINES AND PYRIMIDINOPYRIDINES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
| EP-1893599-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| CN-1946713-A | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-04-11 | — | — | CN | disclosed |
| WO-2006134378-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | KMT2A 3486/4885PKM 4050/4885SIGMAR1 4534/4885 |
| US-20190241605-A1 | HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS | PDXK, PHKG1, DTYMK | KMT2A 3417/4885PKM 150/4885SIGMAR1 4493/4885 |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | FGFR1, FGFR3, FGFR2 | KMT2A 3139/4885PKM 3759/4885SIGMAR1 4815/4885 |
| US-20190233418-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | KMT2A 3486/4885PKM 4050/4885SIGMAR1 4534/4885 |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KMT2A 3561/4885PKM 1909/4885SIGMAR1 3768/4885 |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | FGFR1, FGFR3, FGFR2 | KMT2A 3486/4885PKM 4050/4885SIGMAR1 4534/4885 |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SNCA, NLN, HTT | KMT2A 1459/4885PKM 844/4885SIGMAR1 1324/4885 |
| US-11091509-B2 | HPPK inhibitors useful as antibacterial agents | PDXK, PHKG1, DTYMK | KMT2A 3417/4885PKM 150/4885SIGMAR1 4493/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KMT2A 3561/4885PKM 1909/4885SIGMAR1 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.